Compounded · §503A · Low-dose preparation
Weekly compounded semaglutide microdose
A low-dose weekly semaglutide injection, prepared on a per-patient basis by a US-licensed compounding pharmacy for patients prioritizing tolerability or maintenance dosing under clinician guidance.
- Once-weekly low-dose subcutaneous injection
- Compounded semaglutide prepared per-patient under §503A
- Tolerability-first dosing under clinician guidance
- Flat $179/month — Pallas's lowest entry point
Cash-pay price
$179/mo
Cash-pay only; not billed to insurance. Eligibility determined by a US-licensed clinician.
About
What is Semaglutide microdose?
A low-dose compounded semaglutide injection, prepared per-patient by a US-licensed compounding pharmacy under §503A. Designed for patients prioritizing tolerability — for example, those who are sensitive to GI side effects, who responded well at a low dose and want to remain there as a maintenance protocol, or for whom a lower clinically-appropriate dose is documented by their clinician.
Per-patient compounding · §503A
Microdose preparations are prepared on a per-patient basis when a licensed clinician documents a clinical need for a dose strength below those commercially manufactured — for example, tolerability sensitivity or long-term maintenance dosing.
Dosing
Dosing & schedule
Your clinician determines whether a low-dose protocol is clinically appropriate based on your history. Microdose schedules are individualized — there is no fixed titration.
How it works
01
Complete your online intake
A short, clinical questionnaire — about 5 minutes. Honest answers help your clinician give the best recommendation.
02
A US-licensed clinician reviews
A licensed clinician in your state reviews your intake and decides whether a prescription is clinically appropriate. They may message you for follow-up if needed.
03
Ships from a US-licensed pharmacy
If approved, your prescription is dispensed by a US-licensed pharmacy and shipped to your door in discreet packaging.
Safety
Important safety information
GLP-1 medications can cause nausea, vomiting, diarrhea, constipation, and abdominal discomfort, particularly during dose increases. Rare but serious risks include pancreatitis, gallbladder disease, kidney injury from dehydration, and — based on animal studies — a possible risk of thyroid C-cell tumors. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use these medications. Always disclose your full medical history to your clinician.
Compounded preparations are not FDA-approved, are not generic versions of any brand-name GLP-1 medication, and have not been evaluated by the FDA for safety, efficacy, or quality. Outcomes from the pivotal clinical trials of FDA-approved Wegovy®, Ozempic®, Zepbound®, or Mounjaro® have not been clinically established for compounded preparations.
Low-dose protocols are individualized by your clinician. They are not a clinical equivalent of any FDA-approved product at any dose strength.
FAQ
Common questions
Pallas does not make comparative claims between compounded preparations and FDA-approved brand-name products. The microdose is a compounded preparation prepared per-patient under §503A, not a version of Wegovy®. Your clinician determines whether a low-dose protocol is appropriate for your specific situation.
Microdose protocols are typically appropriate for patients who are sensitive to GI side effects at standard doses, who want to remain at a low maintenance dose long-term, or for whom a lower clinically-appropriate dose has been documented by their clinician.
The compounded semaglutide microdose is $179/month — Pallas's lowest-priced GLP-1 entry point. Pricing is flat with no insurance routing.
No. Pallas is a cash-pay service. Insurance is not currently billed for any medication on the platform. Pricing is flat and disclosed up front — what you see is what you pay.
Complete a short clinical intake — usually under 5 minutes. A US-licensed clinician reviews your history, decides whether a prescription is clinically appropriate, and (if approved) sends it to a US-licensed pharmacy that ships directly to you in discreet packaging.
Yes. There is no long-term contract. You can pause or cancel your subscription at any time from your patient portal. Refunds are handled on a case-by-case basis per our terms.
Start your visit
